NaviGate Cardiac Structures
NaviGate Cardiac Structures is a private Lake Forest, California medical device company (founded 2011, 1–10 employees) developing transcatheter solutions to treat tricuspid regurgitation in the structural heart market.
- Company typePrivate
- Founded2011
- HeadquartersLake Forest, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What NaviGate Cardiac Structures does
NaviGate Cardiac Structures is a privately held, for-profit medical device developer founded in 2011 and headquartered in Lake Forest, California, with a reported headcount of 1–10 employees. Per its own short description, the company develops transcatheter solutions for the treatment of tricuspid regurgitation, placing it in the structural heart / transcatheter valve intervention segment adjacent to the broader transcatheter mitral valve market, which third-party data sizes at a projected $2.49 billion by 2030 growing at a 9.0% CAGR.
The company's leadership team is small and disclosed only at the executive level: R.C. Quijano serves as Chief Technology Officer and Peter Hinchliffe serves as President and CEO. No further management, board, scientific advisory, or clinical advisory members are documented in the input. The public-facing website (navigatecsi.com) returned a non-substantive / corrupted scrape in the source data, so no product names, pipeline stages, regulatory filings, study sites, design specifics, or platform architecture can be evidenced from the company's own material at this time.
No revenue model, pricing model, distribution channel, partnership, customer logo, funding round, investor, subsidiary, geographic market served, regulatory milestone, certification, patent, or award is documented in the input. Business model mechanics — how the company intends to monetize (e.g., direct hospital sales, licensing to a strategic, royalty stream following CE mark / FDA approval) — are therefore not stated in the source material. The overall evidentiary base is thin: the company is identifiable and positioned in a real, growing clinical segment, but commercial, financial, and operational specifics are absent.
NaviGate Cardiac Structures firmographics
Firmographics- Name
- NaviGate Cardiac Structures
- Website
- https://navigatecsi.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- NaviGate Cardiac Structures is a private Lake Forest, California medical device company (founded 2011, 1–10 employees) developing transcatheter solutions to treat tricuspid regurgitation in the structural heart market.
- Ownership category
- akta.pro rank
NaviGate Cardiac Structures industry classification
Industry- Product category
- Structural Heart Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Structural Heart Valves (TAVR/SAVR) & Valve Repair (HLAHAFAB)
- akta.pro secondary industry
- Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)
Keywords
Where NaviGate Cardiac Structures is headquartered
LocationHeadquarters
- HQ city
- Lake Forest
- HQ country
- United States
- HQ region
- North America
Markets served
NaviGate Cardiac Structures business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
NaviGate Cardiac Structures product offering
Product offeringCore offering
NaviGate Cardiac Structures develops transcatheter solutions for the treatment of tricuspid regurgitation. The company focuses on minimally invasive cardiac devices designed to address structural heart disease, specifically targeting the tricuspid valve. Its work sits within the broader transcatheter mitral and tricuspid valve market, which is projected to reach $2.49 billion by 2030 at a 9.0% CAGR.
Differentiator
Problem solved
Functional benefit
Products and services
- Transcatheter Tricuspid Valve Solutions
Companies that use NaviGate Cardiac Structures
Customer profileIdeal customer profiles1 record
NaviGate Cardiac Structures technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
NaviGate Cardiac Structures partnerships and signals
Strategic signalScale indicators1 record
Recent moves1 record
Expansion highlights2 records
NaviGate Cardiac Structures competitors and assessment
Company assessmentBroad incumbents
- Abbott: Diversified medical device major with the TriClip transcatheter tricuspid repair system (formerly from its acquisition of Evalve-adjacent tricuspid assets). Directly comparable as a transcatheter tricuspid competitor with deep clinical, regulatory, and commercial resources.
- Medtronic: Major structural heart player with transcatheter valve programs across aortic, mitral, and tricuspid indications. Comparable to NaviGate as a transcatheter valve developer with significant R&D infrastructure and global commercial reach.
- Edwards Lifesciences: Global structural heart leader developing transcatheter tricuspid platforms including the EVOQUE and PASCAL systems. Highly comparable as a transcatheter valve developer addressing tricuspid regurgitation, though operating at vastly greater scale and across many cardiovascular indications.
Emerging players
- InnovHeart: Italian developer of transcatheter mitral and tricuspid valve replacement technologies (Saturn system). Comparable as an emerging transcatheter valve company targeting tricuspid regurgitation.
- Cardiac Dimensions: Developer of the Carillon mitral contour system, with adjacent transcatheter tricuspid development activity. Comparable as a small-to-mid stage structural heart company developing transcatheter valve/repair technologies for under-treated indications.
- LuxMed Systems: Early-stage developer of transcatheter tricuspid repair technology. Comparable emerging private competitor working on minimally invasive solutions for tricuspid regurgitation.
Direct peers
- CroíValve: Dublin-based developer of a transcatheter tricuspid coaptation device for treating tricuspid regurgitation. Directly comparable niche player competing in the same transcatheter tricuspid space as NaviGate.
- 4C Medical Technologies: Early-stage transcatheter mitral and tricuspid valve developer (e.g., AltaValve). Highly comparable as a similarly sized, venture-backed company focused on transcatheter solutions for under-served valve indications.
- TRiCares: European developer of the Topaz transcatheter tricuspid valve replacement system. Highly comparable as a similarly focused, similarly small private competitor in the transcatheter tricuspid space.
Regional players
- Venus Medtech: China-based structural heart company developing transcatheter valve replacement systems including tricuspid programs. Comparable as a transcatheter valve developer with overlapping technology focus, though primarily serving the China market.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights4 records
Customer concentration
NaviGate Cardiac Structures social profiles
Digital presenceNaviGate Cardiac Structures financial estimates
Financial estimateRevenue estimate
Valuation estimate
NaviGate Cardiac Structures leadership team
Management profileNumber of profiles
Profiles2 records
NaviGate Cardiac Structures funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NaviGate Cardiac Structures M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NaviGate Cardiac Structures
What does NaviGate Cardiac Structures do?
NaviGate Cardiac Structures develops transcatheter solutions for the treatment of tricuspid regurgitation. The company focuses on minimally invasive cardiac devices designed to address structural heart disease, specifically targeting the tricuspid valve. Its work sits within the broader transcatheter mitral and tricuspid valve market, which is projected to reach $2.49 billion by 2030 at a 9.0% CAGR.
When was NaviGate Cardiac Structures founded?
NaviGate Cardiac Structures was founded in 2011. It employs 1 to 10 people.
Where is NaviGate Cardiac Structures based?
NaviGate Cardiac Structures is headquartered in Lake Forest, United States, in the North America region.
Who are NaviGate Cardiac Structures's main competitors?
Broad incumbents on record are Abbott, Medtronic and Edwards Lifesciences. Emerging players are InnovHeart, Cardiac Dimensions and LuxMed Systems. Direct peers are CroíValve, 4C Medical Technologies and TRiCares. Venus Medtech is listed as a regional player.
Does NaviGate Cardiac Structures have an API?
No public API is recorded for NaviGate Cardiac Structures.
What industry is NaviGate Cardiac Structures in?
NaviGate Cardiac Structures's product category is Structural Heart Devices. Its primary akta.pro industry code is HLAHAFAB, Structural Heart Valves (TAVR/SAVR) & Valve Repair, with a secondary code of HLAHAFAL, Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation). Its NAICS code is 339112 and its SIC code is 3841.